Source: Genetic Engineering & Biotechnology News, June 2025
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors.
The study, by an international group of scientists headed by a team at Newcastle University, also points to a combination treatment strategy for treating ICB-resistant metastatic skin cancers, suggesting that the same approach may also be beneficial in the immunotherapy of other types of solid tumor.